WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement today on the decision by David J. Kappos, Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (PTO), to withdraw the agency’s proposed rules restricting continuation and claims practice, which had been opposed by BIO and challenged in court by GlaxoSmithKline:
